Currently set to Index
Currently set to Follow
search
ask age2b
CART

Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis

By AGE2B team
November 7, 2021
0
0

Main idea: The safety profile of 5-grass tablet in pediatric allergic rhinitis patients aged 5 to 9 years was consistent with safety findings in older patients.

Abstract

Although 5-grass pollen sublingual immunotherapy has a good safety profile in controlled clinical trials, additional safety information among pediatric patients in a real-world setting would be useful.

The objective of the study was to document the safety of 5-grass tablet among children aged 5 to 9 years with allergic rhinoconjunctivitis.

This multi-center, observational study included allergy immunotherapy-naïve 5- to 9-year-old children with grass pollen-induced allergic rhinoconjunctivitis prescribed with 5-grass tablet daily (3-day dose escalation to 300 indexes of reactivity [IR]). Patients were followed up daily for safety and tolerability over the first 30 treatment days.

Results: Three hundred seven children (mean age, 7.1 years) were enrolled. 58% were confirmed as polysensitized, and 36% had mild-to-moderate asthma. Of 307 patients 233 (76%), some patients had side effects including throat irritation, oral pruritus, oral paresthesia. 16 of 307 (5.2%) patients withdrew because of side effects. More than half of the side effects lasted less than 2 days.

Source Annals of Allergy, Asthma & Immunology

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.